FIGURE 1 Given the role of GLP-1 in glycaemic control, the anti-apoptotic, growth-stimulating and insulin secretion-promoting effects on pancreatic -cells, the ability to re-sensitize the cellular insulin-signaling, minor side effects, good tolerance by normoglycemic patients and the fact that GLP-1 does not desensitize, synthetic GLP-1R agonists have been on the market for decades to treat type 2 diabetes mellitus (T2DM) or, more recently, to improve weight loss (Drucker, 2018)
If you're still in titration (increasing doses weekly or bi-weekly), you haven't yet reached the dose needed for full effect
While serious events are rare, they are more likely when the medication concentration becomes excessive
Early CagriSema trials show weight loss that matches or exceeds these results at comparable time points
9,10 These actions change eating behaviour: the anticipatory food reward for looking forward to eating certain (delicious) foods decreases, while consummatory food reward (the pleasure offered by eating) increases